Related Experiment Video
Updated: Jun 2, 2026
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Intrasplenic vaccination against experimental melanoma
1ROGER WILLIAMS MED CTR,DEPT SURG,PROVIDENCE,RI 02908. BROWN UNIV,RHODE ISL HOSP,DEPT PEDIAT,PROVIDENCE,RI 02908. NCI,CELL BIOL LAB,NIH,BETHESDA,MD 20892.
International Journal of Oncology
|May 5, 2011
Summary
A novel melanoma-associated antigen B700 vaccine stimulates antibody production and enhances cellular immunity, leading to reduced tumor growth and increased survival rates in preclinical models.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- The formalinized extracellular antigen (fECA) vaccine derived from B16 F10 melanoma cells contains melanoma-associated antigen B700 as its key component.
- Understanding the immune response to B700 antigen is crucial for developing effective melanoma therapies.
Purpose of the Study:
- To investigate the immunomodulatory effects of prophylactic intrasplenic inoculation of B700 antigen.
- To assess the impact of B700 antigen on both humoral and cellular immune responses against melanoma.
Main Methods:
- Mice were inoculated with B700 antigen via intrasplenic injection.
- Humoral responses were measured by antibody production and their antiproliferative effects on melanoma cells.
- Cellular immune functions, including natural killer (NK) cell and lymphokine-activated killer (LAK) cell activities, were evaluated.
- T lymphocyte activation was assessed by CD25 surface antigen and IL-2 R alpha mRNA expression.
Main Results:
- B700 antigen inoculation induced antibodies with in vitro antiproliferative effects on B16 F10 melanoma cells.
- Splenocyte assays revealed increased NK cell and LAK cell activities post-inoculation.
- Intrasplenic B700 antigen administration upregulated CD25 expression on T lymphocytes and IL-2 R alpha mRNA levels.
Conclusions:
- Prophylactic B700 antigen vaccination elicits both humoral and cellular immune responses.
- These immune responses contribute to decreased primary tumor growth and improved survival rates in melanoma-bearing mice.
- B700 antigen shows potential as a therapeutic agent in melanoma treatment.
